Abstract
ABSTRACTIntroduction: Initially thought to be a retinal vasculopathy macular telangiectasia (MacTel) type 2 is now believed to be a primary neuroglial disorder with secondary vascular changes. To date there is no evidence for an effective treatment of nonproliferative MacTel type 2. Patients with proliferative MacTel type 2 with decreasing visual function may benefit from intravitreal injection of vascular endothelial growth factor inhibitors.Areas covered: A medline search using Pubmed and google scholar was conducted to identify research studies providing an overview of epidemiology, clinical features, imaging characteristics and structure-function correlation, with an emphasis on currently available treatment options for MacTel type 2.Expert commentary: The nature of the initiating event in MacTel type 2 remains obscure. Identification of a genetic basis would be a great advance but has so far been elusive. It is likely that derangement of outer retinal metabolism plays a major role.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
